Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Padnarsertib in advanced solid malignancies or NHL
NCT02702492Phase 1Terminated
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jun 2016
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of padnarsertib in solid tumor and non-Hodgkin lymphoma (NHL) (13 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoints: Maximum Tolerated Dose up to 44 weeks, Dose Limiting Toxicities and 7 more. Started Jun 2016; status: terminated.
02
Drugs
padnarsertib
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02702492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02702492.